No Data
Hengrui Medicine's Subsidiaries Get Nod to Trial Anti-Tumor Drugs
Jiangsu Hengrui Pharmaceuticals (600276.SH): Bought back a total of 5.53 million shares.
On March 4, Gelinghui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that as of February 28, 2025, the company had repurchased a total of 5,530,044 shares through centralized bidding Trade, accounting for 0.09% of the company's total share capital. The highest transaction price was 57.01 yuan/share, and the lowest price was 39.00 yuan/share, with a total amount paid of 233,902,752.60 yuan (excluding transaction fees). The above repurchase complies with relevant laws and regulations as well as the company's predetermined share repurchase plan.
Jiangsu Hengrui Medicine Obtains Clinical Trial Approvals for Two Injectable Drugs; Shares Down 3%
Jiangsu Hengrui Pharmaceuticals (600276.SH): SHR-A2009 injection and Adebali monoclonal antibody injection have obtained approval for clinical trials.
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that recently, its subsidiary Suzhou Shengdiya Biomedical Co., Ltd...
Hengrui Medicine Unit Gets Clinical Trial Nod for Hyperlipidemia Drug
The wave of AI in Medical is sweeping: the potential of the macromolecule new drug market is highlighted and imaging products are "going overseas" into Emerging Markets | Focus
① Some executives from pharmaceutical companies have stated that "currently, the discovery of small molecule drugs is very challenging; finding potential molecules and structures is already quite difficult, while there is still significant potential in the discovery and design of large molecule new drugs." ② Currently, the application maturity of AI technology in the imaging field is relatively high, and relevant manufacturers have revealed that the market potential for AI imaging large models in Belt and Road Initiative Concept countries is quite extensive.
Shareholders in Jiangsu Hengrui Medicine (SHSE:600276) Are in the Red If They Invested Three Years Ago
